Abstract 1398
Background
Liver metastasis is recognized as a risk factor for metastatic breast cancer (MBC). Hepatic arterial infusion chemotherapy (HAIC) is a treatment option for MBC in patients with extensive hepatic lesions; however, there is no standard regimen, and the effects have not been well discussed.
Methods
We reviewed our medical records of MBC to extract patients with resistance to standard systemic chemotherapies, critical liver metastasis, and who received HAIC with an FEM regimen (5-fluorouracil 333 mg/m2 [weekly], epirubicin 30 mg/m2 [every 4 weeks], and mitomycin-C 2.7mg/m2 [every 2 weeks]) in our institute.
Results
We identified 58 patients who received HAIC (median age at initiation, 58 [30-80] years) in our institute between 2002 and 2017. Their ECOG performance (PS) statuses were as follows: PS0, 44; PS1, 10; and PS 2, 4. Their receptor statuses were as follows: hormone receptor positive (HR+)/HER2+, 9; HR+/HER2-, 38; HR-/HER2+, 4; HR-/HER2-, 7. The median number of systemic regimens (including endocrine therapy) prior to HAIC was 6 (2-17). The median number of liver metastases was 8 (1-≥20); the median maximum size of liver metastases was 5.2 cm (1.6-20.1). The median number of extrahepatic metastatic site was 2 (0-5). The median overall survival (days) was as follows: overall, 371 (95% confidence interval [CI] 260-475); HER2+, 441 (95% CI 166-652); HER2-, 344 (95% CI 279-475). The median time to progression of intrahepatic lesions (days) was as follows: overall, 303 (95% CI 184-491); HER2+, 491 (95% CI 90-NR); HER2-, 298 (95% CI 184-387). An objective response (CR+PR) of intrahepatic lesions was observed in 37 patients (63.8%). The reasons for the discontinuation of HAIC included: progression of extrahepatic lesion(s), 20 (34.5%); progression of intrahepatic legion(s), 16 (27.6%); clinical progression, 7 (12.1%); transition to maintenance therapy, 6 (10.3%); catheter-related events, 5 (8.6%); and duodenal ulcer, 1 (1.7%).
Conclusions
HAIC with an FEM regimen offers an effective treatment for patients with liver metastasis from MBC that shows resistance to systemic therapy.
Clinical trial identification
Legal entity responsible for the study
Junichiro Watanabe.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract